

DRUG PRIOR AUTHORIZATION COMMITTEE MEETING
June 21, 2012
600 West Main Street, Interpretative Center
Jefferson City, MO 65101

Committee Members Present

Conrad Balcer, D.O.
Stephen Calloway, RPh
Laine Young-Walker, M.D.
Pat Bryant, PharmD
Morgan Sperry, PharmD, (alternate)

MO HealthNet Staff Present:

Rhonda Driver, RPh, Director of Pharmacy
Mark Roaseau, RPh, Clinical Pharmacist
Andrew Haslag, Fiscal & Administrative Manager
Jenna Twehus, RN
Mary Heet, RN
Allison Lauf, RN
Angela Wilson, Unit Supervisor
Ashley Wilson, Medicaid Pharmaceutical Technician
Lisa Smith, Medicaid Pharmaceutical Technician
Jetawn Smith, Medicaid Pharmaceutical Technician
Tasia Roberts, Clerical
Whitney Maloy, Clerical

Contractors in Attendance:

Rick Pope, PharmD, First Health Services
Jennifer Kemp-Cornelius, PharmD, ACS
Josh Moore, ACS
Katie Wilbers, ACS
Beth Walther, Student
David Baker, Student

Others Attending:

Lon Lowrey, Novartis	Matt Bradley, Novartis	Mike Donze, Boehringer-Ingelheim	Jeff Knappen, Allergan
David Large, Boehringer-Ingelheim		Stephanie Keithly, Novo Nordisk	Jeff Himmelberg, GSK
Mandy Schnelten, Novo Nordisk		Jim McNamara, ViiV Healthcare	Todd Houldsworth, J&J
Chris Beal, Otsuka	Robert Calder, Merck	Berend Koops, Merck	Lisa Pulkrabek, Astellas
Matt Jackson, Astellas	Kevin Brown, Astellas	Jerry Clewell, Abbott	Eric Blake, Merck
Kristin Crouch, Vertex	Eric Gardner, Vertex	Rupa Shah, Purdue	Chet Steckler, Purdue
Mary Cook, Purdue	Julie Cleavinger, B&L	Mike Ketcher, Novo Nordisk	Debbie King, Amgen
Dave Sproat, BMS	Suzanne Goot, Abbott Laboratories	Del Deem, Astra Zeneca	Dean Grath, Pfizer
Kristian Starner, Brent Hemphill & Associates		Scott Edelhauser, Alcon Laboratories	Jim Baumann, Pfizer

Many names on the sign-in sheet were illegible. Sign in sheet on file for review.

Welcome, Introductions and Opening Remarks	Rhonda Driver, RPh, Director of Pharmacy called the meeting to order. Pat Bryant introduced Dr. Amy Pope, who is finishing up her fellowship with him; Josh Moore, ACS, introduced two students, David Baker and Beth Walther. Rhonda announced that the remaining Drug PA meetings would be held at the Secretary of State Interpretative Center located at 600 West Main Street, Jefferson City, MO 65101.
Minutes Approval	Minutes of the March 15, 2012, meeting were reviewed and approved as submitted. Conrad Balcer moved to accept the meeting minutes; Pat Bryant seconded the motion. (See Roll Call Vote)
Pharmacy Program/Budget Update	Andrew Haslag provided a Budget Update. He stated that with the fiscal year about to end, we were going to make our ends meet. He said that the appropriations bills had been passed and that it is just waiting for Governor Nixon's signature. Mr. Haslag said that there weren't a lot of pharmacy issues for the Fiscal Year 13 budget. A fair amount of generic savings has been booked as a couple of high profile drugs should be going generic in the next few months. We pay for the Blind Pension pharmacy benefit which is about 10-11 million dollars; Mr. Haslag stated that this money has been moved out of our budget, but we will administer the program. Rhonda Driver reviewed the 5010 D.0 transaction change that went into effect for the entire nation on January 1; it is a CMS mandate. Ms. Driver stated that dedicated outreach has been done for at least two and half months to work with systems and software vendors to make sure that they are ready. From a MO HealthNet perspective, June 30 is the last day to send transactions using the old standard. Mark Roaseau discussed the ICD-10 conversion and stated that CMS is making a site visit in July with regards to ICD-10. Ms. Driver stated that there is a lot of code to remediate to prepare for the implementation to ICD-10. Ms. Driver also stated that the coding is hard and fast in MMIS and we have to figure out how to define some of those codes again so that everyone codes it the right way. Ms. Driver stated that the Health Home Initiative is still moving forward.
DUR Report	Rhonda Driver reported the DUR Board reviewed, and concurred with the recommendations made by the Drug Prior Authorization (PA) Committee in March. These edits have been scheduled for implementation.
Voting on a Chair for the Drug PA Committee	Laine Young-Walker nominated Stephen Calloway to be made chair of the board. Pat Bryant seconded the nomination. Members voted to make Stephen Calloway chair of the Drug PA Committee. (See attached roll call)
Old Business	
Implementation Schedule	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule included the items that were discussed in March and April. SNRI and SSRI edits have been ratified and those are schedule to close out the quarter. Schedules may be found on the MHD web page at http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf
New Business	Rhonda Driver reviewed the new drug products that were identified for the quarter that included January, February, and March of 2012, and the recommended status within the clinical program.
New Drug Review	Discussion – A listing of products recommended for open access, clinical edit, as a preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout to all attending. <ul style="list-style-type: none"> • Public Hearing – Rupa Shah, Clinical Pharmacist, with Purdue Pharma LP presented information about the product Intermezzo.

	<ul style="list-style-type: none"> ● Decision – Members voted to accept the new drug recommendations as presented. (See Roll Call Vote)
Clinical Edit (CE) Review:	
ADHD Therapy-Clinical Edit	<ul style="list-style-type: none"> ● Discussion –Ms. Driver reviewed the addition of dosing limitations for pediatric and adult doses. ● Public Hearing-No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Botulinum Toxin-Clinical Edit	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the approval and denial criteria. ● Public Hearing-Jeff Knappen, Regional Healthcare Quality Manager, with Allergan, asked that the Board consider two things: change the word detrusor instability to over activity because that would be consistent with the labeling and consider adding ICD-9 code 596.54. He suggested that it may help the providers bill to a higher degree of specificity. ● Decision –The Committee voted to accept this edit and review the suggestion. (See Roll Call Vote)
PDL Annual Review:	
GLP-1 Receptor Agents	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing-No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Amylin Analogs	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing-No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Cox II Inhibitors	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing-No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Hepatitis C Agents	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents, noting that both protease inhibitors are recommended for preferred status. ● Public Hearing-No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Proton Pump Inhibitors	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Topical Androgenic Agents	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing the preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Beta Blockers	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Calcium Channel Blockers: Non-Dihydropyridine	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered.

	<ul style="list-style-type: none"> ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Calcium Channel Blockers: Dihydropyridine	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Calcium Channel Blockers/ ARB Agents	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria documents, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Dipeptidyl Peptidase-4 Inhibitor	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria documents, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Onychomycosis Antifungal Agents	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria documents, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Ribavirins	<ul style="list-style-type: none"> ● Discussion – Ms. Driver reviewed the criteria document, reviewing preferred and non-preferred agents. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Topical Immunomodulators	<ul style="list-style-type: none"> ● Discussion – Ms. Driver stated that there is no change recommended for this class. ● Public Hearing- No comments were entered. ● Decision – The Committee voted to accept this edit as presented. (See Roll Call Vote)
Preferred Drug List Announcement	A handout of therapeutic categories to be considered for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page.
Xerox Update	Jennifer Kemp-Cornelius, PharmD, reviewed the call center statistics for Skeletal Muscle Relaxants and Fibromyalgia. Ms. Kemp-Cornelius went over the approval and denial criteria for both Skeletal Muscle Relaxants and Fibromyalgia. She also reviewed the per member-per month costs for agents that are most prescribed. Ms. Kemp-Cornelius asked if there were any edits that the Board was interested in looking at utilization for at the next meeting. She stated that her team would look at the short-acting narcotics for the September 20, 2012, meeting.
Program Utilization: Top 25 Drugs by Cost	Jennifer Kemp-Cornelius, PharmD, reviewed the Top 25 Drugs by Cost and provided two forms, one showing by Paid Amount and one by Claims.
Call Center Statistics/ CyberAccess Reports	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity was shared. Ms. Kemp-Cornelius reviewed how many sites/physical locations are trained and have access to CyberAccess and how many prescribers and active users CyberAccess has. She stated that the psychology and counseling sites would be the next group that Xerox would focus on would making changes in CyberAccess to allow them to request their prior authorizations through Cyber rather than calling in or sending a fax. She also stated that during the month of May, a major change was made to the medical pre-certification pages and as a result, they activity was not getting logged so they would work on getting that fixed.

Adjourn

The meeting was adjourned at approximately 12:30pm. The next meeting of the Drug PA Committee is scheduled for September 20, 2012, and is expected to be held at the Secretary of State Building at 600 West Main Street. Attendees were advised to check the [calendar of events](#) on the MHD website for meeting location changes over the next few months. (See attached roll call)

Roll Call Votes – June 21, 2012

Member	Minutes	New Drug Review	ADHD Therapy Clinical Edit	Botulinium Toxin Clinical Edit	GLP-1 Receptor Agonists	Amylin Analogs	Cox II Inhibitors	Hepatitis C Agents
Conrad Balcer, D.O.	M	M	M	M	M	M	M	S
Pat Bryant, Pharm.D.	S	S	S	S	S	S	S	M
Steven Calloway, R. Ph	Y	Y	Y	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	A	A	A	A	A	A	A	A
Laine Young-Walker, M.D.	A	Y	Y	Y	Y	Y	Y	Y

Member	Proton Pump Inhibitors	Topical Androgenic Agents	Beta Blockers	Calcium Channel Blockers: Non-Dihydropyridine	Calcium Channel Blockers: Dihydropyridine	Calcium Channel Blockers/ ARB Agents	Dipeptidyl Peptidase-4 Inhibitor
Conrad Balcer, D.O.	M	Y	Y	M	S	M	M
Pat Bryant, Pharm.D.	S	S	M	S	Y	S	S
Steven Calloway, R. Ph	Y	Y	Y	Y	Y	Y	Y
Gene Forrester, R. Ph.	A	A	A	A	A	A	A
Laine Young-Walker, M.D.	Y	M	S	Y	M	Y	Y

Member	Onycomycosis Antigunals	Ribavirins	Topical Immunomodulators	Adjourn	Voting on a Chair for the Board
Conrad Balcer, D.O.	S	M	M	M	Y
Pat Bryant, Pharm.D.	M	S	S	S	S
Steven Calloway, R. Ph	Y	Y	Y	Y	
Gene Forrester, R. Ph.	A	A	A	A	A
Laine Young-Walker, M.D.	Y	Y	Y	A	M